Cyteir Therapeutics is developing the next generation of synthetic lethal therapies targeting cancers and autoimmune diseases with specific gain-of-function abnormalities. Our current lead program targets RAD51 to induce synthetic lethality in diseases with a gain-of-function in the gene AID (also called AIDCA).
Cyteir Therapeutics is developing the next generation of synthetic lethal therapies targeting cancers and autoimmune diseases with specific gain-of-function abnormalities. Our current lead program targets RAD51 to induce synthetic lethality in diseases with a gain-of-function in the gene AID (also called AIDCA).
Cyteir Therapeutics is developing the next generation of synthetic lethal therapies targeting cancers and autoimmune diseases with specific gain-of-function abnormalities. Our current lead program targets RAD51 to induce synthetic lethality in diseases with a gain-of-function in the gene AID (also called AIDCA).